Mavacamten Controlled Hypertrophic Cardiomyopathy for >1 Year

Mavacamten Managed Hypertrophic Cardiomyopathy for >1 12 months

WASHINGTON – Treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy who remained on treatment with the investigational agent mavacamten for a median of 62 weeks continued to show the same level of safe response to the drug as seen after the first 30 weeks on treatment in the pivotal trial for this agent. The new findings…